These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 22163337)

  • 1. Neutralizing antibody response to hepatitis C virus.
    Wang Y; Keck ZY; Foung SK
    Viruses; 2011 Nov; 3(11):2127-45. PubMed ID: 22163337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
    Ruwona TB; Giang E; Nieusma T; Law M
    J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
    Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.
    Urbanowicz RA; Wang R; Schiel JE; Keck ZY; Kerzic MC; Lau P; Rangarajan S; Garagusi KJ; Tan L; Guest JD; Ball JK; Pierce BG; Mariuzza RA; Foung SKH; Fuerst TR
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
    Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH
    PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    Ahsan A; Dar S; Hassan F; Ghafoor F; Yousuf MH; Shahzad-Ul-Hussan S
    PLoS One; 2021; 16(8):e0256816. PubMed ID: 34449828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
    El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
    PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
    Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
    Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
    Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development.
    Pierce BG; Felbinger N; Metcalf M; Toth EA; Ofek G; Fuerst TR
    Viruses; 2024 May; 16(5):. PubMed ID: 38793684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.
    El Abd YS; Tabll AA; El Din NG; Hosny Ael-D; Moustafa RI; El-Shenawy R; Atef K; El-Awady MK
    Virol J; 2011 Aug; 8():391. PubMed ID: 21819575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
    Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
    Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
    Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
    Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.
    Flyak AI; Ruiz S; Colbert MD; Luong T; Crowe JE; Bailey JR; Bjorkman PJ
    Cell Host Microbe; 2018 Nov; 24(5):703-716.e3. PubMed ID: 30439340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.